Lung Cancer: Advances in Current Treatment Modalities and Patient Classification
Symposium - New York City, United States
Lung cancer is one of the most common and deadliest cancers worldwide. The majority of patients present with advanced disease and despite decades of work, overall survival rates are still very low. Recent advances in treatment modalities have increased the risk/benefit ratio for these patients and this may translate into increased survival rates. A better understanding of the genetic heterogeneity of lung cancer has led to a new patient classification scheme that may help inform on patient selection for future trials.
The topics to be discussed in this symposium include: lung cancer classification, common mutations and insights for patient selection, the use of intraoperative chemotherapy and minimally invasive surgery to treat thoracic cancers, and a discussion on insights from clinical trials using targeted and combination chemotherapy for small cell and non-small cell lung cancers.
Organization: New York Academy of Sciences
(Courtesy of Lung cancer, via jthoracdis.com)
Lung Cancer: Advances in Current Treatment Modalities and Patient Classification
Tuesday, March 25, 2014 | 12:00 PM - 4:00 PM
The New York Academy of Sciences
250 Greenwich St, 40th Floor, New York City, United States
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.
